Globus Medical ( (GMED) ) has released its Q4 earnings. Here is a breakdown of the information Globus Medical presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Globus Medical, Inc., headquartered in Audubon, Pennsylvania, is a leading company in the musculoskeletal technology sector, specializing in innovative products designed to enhance surgical outcomes for patients with musculoskeletal disorders.
The company recently announced its financial results for the fourth quarter and full year of 2024, showcasing significant growth in net sales and profitability. The results highlight the successful integration of NuVasive, contributing to the company’s strong financial performance.
In the fourth quarter of 2024, Globus Medical reported worldwide net sales of $657.3 million, marking a 6.6% increase compared to the same period in the previous year. The GAAP net income for the quarter was $26.5 million, with a non-GAAP diluted EPS of $0.84. For the full year, worldwide net sales reached $2.52 billion, a substantial 60.6% increase from 2023, driven by the merger and increased product volumes. The full-year GAAP net income was $103 million, and the non-GAAP diluted EPS stood at $3.04.
The company’s strategic focus on innovation and integration has led to a robust financial performance, despite the complexities that come with mergers. The management highlighted the successful launch of new products and maintained a disciplined approach in operational excellence and cost management.
Looking ahead, Globus Medical remains optimistic about its growth trajectory, reaffirming its 2025 revenue guidance. The company anticipates further operational efficiencies and continued market leadership through innovation and acquisition strategies, positioning itself well for future growth.
